Menu Search
Equities

ONWARD Medical NV

63E:FRA

ONWARD Medical NV

Actions
  • Price (EUR)5.10
  • Today's Change0.08 / 1.59%
  • Shares traded201.00
  • 1 Year change-6.25%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 14:29 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Onward Medical NV, formerly known as GTX Medical BV, is a medical technology company based in the Netherlands. The Company is primarily engaged in developing and commercializing innovative therapies to enable functional recovery for people with spinal cord injury. It develops two technology platforms ARC EX and ARC IM.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-36.18m
  • Incorporated2015
  • Employees99.00
  • Location
    ONWARD Medical NVSchimmelt 2EINDHOVEN 5611ZXNetherlandsNLD
  • Phone+31 402882830
  • Websitehttps://www.onwd.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.